Drug intelligence / Profile preview

tigatuzumab

Development stage: Phase 2
Lead developer: Daiichi Sankyo
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Tigatuzumab is a humanized monoclonal antibody that targets death receptor 5 (DR5), also known as TRAIL receptor 2. It is designed to induce apoptosis in tumor cells by binding to DR5 and activating the extrinsic apoptotic pathway. Tigatuzumab was developed primarily for the treatment of various solid tumors, including colorectal cancer and pancreatic cancer. The drug acts as an agonist of DR5, promoting programmed cell death specifically in cancer cells that overexpress this receptor. Tigatuzumab was originally developed by Daiichi Sankyo.

Other names: tigatuzumab

Targets

TNFRSF10B (DR5)

Beyond the preview

Go deeper on tigatuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tigatuzumab.

Explore the full profile